ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Emergency department utilization and clinical outcomes among patients with gastrointestinal cancers receiving chemotherapy during the first year after diagnosis.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to evaluate Emergency Department (ED) utilization and associated outcomes among patients with gastrointestinal (GI) cancers during the first year following diagnosis.
methodsThis retrospective study was conducted at a comprehensive cancer center and included patients with GI cancers diagnosed between 2018 and 2022 who received chemotherapy. Data collected included baseline characteristics, cancer type and stage, initial treatment plan, and prescribed chemotherapy with number of cycles received. Also, we evaluated ED visits frequency, presenting complaints, hospital admissions, and 1-year mortality.
resultsDuring the study period, a total of 2278 patients were diagnosed with GI cancers and received chemotherapy. The mean age was 57 ± 12.4 (SD), 57.6% were males, and 23.6% were smokers. The majority had colon cancer (n = 769, 33.7%) and rectal cancer (n = 630, 27.6%). The most common Surveillance, Epidemiology, and End Results (SEER) stage was distant (43.7%). Renal and hepatic dysfunction at baseline were recorded in 5.6% and 2.8%, respectively. Surgery combined with chemotherapy was the most common treatment plan (43.2%), and patients received a median (IQR) of 8 (5-12) chemotherapy cycles. Among those patients, 2007 (88.1%) required at least one ED visit, with a median (IQR) of 3 (1-6) visits/patient, and 1971 (86.5%) required at least one hospital admission. The most frequently reported chief complaints were musculoskeletal/pain, GI symptoms, and infections. The 1-year mortality rate was 48.8%.
conclusionIn a large cohort of patients with GI cancers, the majority required ED visits within the first-year following diagnosis, many of which resulted in hospital admissions. Most visits were for musculoskeletal/pain and GI symptoms.
Indexed as
Identifiers
42907682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.